Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke

Inclusion Criteria:

1. Age 18-75 years.

2. The patients were clinically diagnosed with acute ischemic stroke with NIHSS score ≥5 points and ≤15 points,and NHISS score 1a level of consciousness < 1 point.

3. mRS≤1 before stroke onset.

4. Signed and dated informed consent is obtained.

Exclusion Criteria:

1. Patients with transient ischemic attack and those undergoing emergency reperfusiontherapy, including intravenous thrombolysis and emergency thrombectomy.

2. Patients using glucocorticoids, antiarrhythmic drugs (class I and class IIIantiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium,verapamil, etc.), and quinolones within 14 days.

3. Patients with other diseases that may aggravate adverse drug reactions, such asventricular arrhythmias, prolonged QT interval (male: QTc>430ms, female: QTc>450ms),severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis,peripheral neuropathy, seizures, tendon-related diseases, severe immunesystem-related diseases, hematological diseases, active hepatitis or cirrhosis,serious respiratory diseases.

4. Abnormal liver and kidney function: glutamic oxaloacetic transaminase or glutamicpyruvic transaminase exceeds 3 times the upper limit of normal; Direct bilirubin orindirect bilirubin more than 3 times the normal upper limit; Blood creatinineexceeds 1.1 times the upper limit of normal; Creatinine clearance rate≤50ml/min;Urea nitrogen≥ 20mg/dL.

5. Concurrent infection.

6. Blood glucose lower than 3.9 mmol/L.

7. Patients allergy to fluoroquinolones or other antibiotics.

8. Patients with a life expectancy less than 3 months or patients unable to completethe study for other reasons.

9. Not willing to be followed up or poor treatment compliance.

10. Patients who are participating in other clinical studies, or have participated inother clinical studies within 3 months before enrollment, or have participated inthis study.

11. Other conditions not suitable for enrollment.